Literature DB >> 17804422

Oncogenic events triggered by AID, the adverse effect of antibody diversification.

Pablo Pérez-Durán1, Virginia G de Yebenes, Almudena R Ramiro.   

Abstract

The generation of an efficient immune response depends on highly refined mechanisms of antibody diversification. Two of these mechanisms, somatic hypermutation (SHM) and class switch recombination (CSR), are initiated by activation-induced cytidine deaminase (AID) upon antigen stimulation of mature B cells. AID deaminates cytosines on the DNA of Ig genes thereby generating a lesion that can be processed into a mutation (SHM) or a DNA double-strand break followed by a recombination reaction (CSR). A number of mechanisms are probably responsible for regulating AID function, such as transcriptional regulation, subcellular localization, post-transcriptional modifications and target specificity, but the issue remains of how unwanted DNA damage is fully prevented. Most lymphocyte neoplasias are originated from mature B cells and harbour hallmark chromosome translocations of lymphomagenic potential, such as the c-myc/IgH translocations found in Burkitt lymphomas. It has been recently shown that such translocations are initiated by AID and that ataxia-telangiectasia mutated, p53 and ARF provide surveillance mechanisms to prevent these aberrations. In addition, evidence is accumulating that AID expression can be induced in B cells independently of the germinal centre environment, such as in response to some viral infections, and occasionally in non-B cells, at least in certain inflammation-associated neoplasic situations. The most recent findings on AID expression and function and their relevance to the generation of oncogenic lesions will be discussed.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17804422     DOI: 10.1093/carcin/bgm201

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  20 in total

1.  Directed evolution of mammalian anti-apoptosis proteins by somatic hypermutation.

Authors:  Brian S Majors; Gisela G Chiang; Nels E Pederson; Michael J Betenbaugh
Journal:  Protein Eng Des Sel       Date:  2011-12-09       Impact factor: 1.650

2.  Somatic hypermutation analysis in follicular lymphoma provides evidence suggesting bidirectional cell migration between lymph node and bone marrow during disease progression and relapse.

Authors:  Martin Wartenberg; Peter Vasil; Christian Meyer zum Bueschenfelde; German Ott; Andreas Rosenwald; Falko Fend; Marcus Kremer
Journal:  Haematologica       Date:  2013-04-12       Impact factor: 9.941

3.  Nucleosome stability dramatically impacts the targeting of somatic hypermutation.

Authors:  Prashant Kodgire; Priyanka Mukkawar; Justin A North; Michael G Poirier; Ursula Storb
Journal:  Mol Cell Biol       Date:  2012-03-05       Impact factor: 4.272

4.  BCL2 mutations are associated with increased risk of transformation and shortened survival in follicular lymphoma.

Authors:  Cristina Correia; Paula A Schneider; Haiming Dai; Ahmet Dogan; Matthew J Maurer; Amy K Church; Anne J Novak; Andrew L Feldman; Xiaosheng Wu; Husheng Ding; X Wei Meng; James R Cerhan; Susan L Slager; William R Macon; Thomas M Habermann; Judith E Karp; Steven D Gore; Neil E Kay; Diane F Jelinek; Thomas E Witzig; Grzegorz S Nowakowski; Scott H Kaufmann
Journal:  Blood       Date:  2014-12-01       Impact factor: 22.113

5.  Msh6 protects mature B cells from lymphoma by preserving genomic stability.

Authors:  Jonathan U Peled; Rani S Sellers; Maria D Iglesias-Ussel; Dong-Mi Shin; Cristina Montagna; Chunfang Zhao; Ziqiang Li; Winfried Edelmann; Herbert C Morse; Matthew D Scharff
Journal:  Am J Pathol       Date:  2010-10-07       Impact factor: 4.307

Review 6.  The APOBEC3 family of retroelement restriction factors.

Authors:  Eric W Refsland; Reuben S Harris
Journal:  Curr Top Microbiol Immunol       Date:  2013       Impact factor: 4.291

Review 7.  Regulation of Aicda expression and AID activity.

Authors:  Hong Zan; Paolo Casali
Journal:  Autoimmunity       Date:  2013-01-17       Impact factor: 2.815

Review 8.  Activation-induced cytidine deaminase (AID) linking immunity, chronic inflammation, and cancer.

Authors:  Diana Mechtcheriakova; Martin Svoboda; Anastasia Meshcheryakova; Erika Jensen-Jarolim
Journal:  Cancer Immunol Immunother       Date:  2012-04-19       Impact factor: 6.968

9.  Comprehensive FISH probe design tool applied to imaging human immunoglobulin class switch recombination.

Authors:  Jakub Nedbal; Philip S Hobson; David J Fear; Rainer Heintzmann; Hannah J Gould
Journal:  PLoS One       Date:  2012-12-14       Impact factor: 3.240

10.  MicroRNA-155 suppresses activation-induced cytidine deaminase-mediated Myc-Igh translocation.

Authors:  Yair Dorsett; Kevin M McBride; Mila Jankovic; Anna Gazumyan; To-Ha Thai; Davide F Robbiani; Michela Di Virgilio; Bernardo Reina San-Martin; Gordon Heidkamp; Tanja A Schwickert; Thomas Eisenreich; Klaus Rajewsky; Michel C Nussenzweig
Journal:  Immunity       Date:  2008-05-01       Impact factor: 31.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.